Does onsite cytotechnology evaluation improve the accuracy of endoscopic ultrasound-guided fine-needle aspiration biopsy?


BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the preferred modality for the cytological diagnosis of various cancers. Onsite cytopathology interpretation is not available in most centres.

OBJECTIVE: To assess whether the adequacy of tissue sampling assessed by an onsite cytotechnologist improves the diagnostic accuracy of EUS-FNA.

METHODS: The present study is a retrospective review of all patients undergoing solid mass EUS-FNA between September 2005 and August 2007. Patients in group I (September 2005 to August 2006) had cytology slides prepared by an endoscopy nurse. Patients in group II (September 2006 to August 2007) had cytology slides prepared, stained and assessed for adequacy of tissue sampling by a cytotechnologist in the endoscopy suite. The final cytopathological diagnosis (definitely positive, definitely negative or inconclusive) was compared between the two groups.

RESULTS: A total of 49 EUS-FNA procedures were performed in 47 patients in group I and 60 EUS-FNA procedures in 55 patients in group II. Pancreatic masses were the most common target site in both groups. The total number of needle passes was 105 in group I (mean 2.14 passes per patient; range one to four needle passes) and 158 in group II (mean 2.63 passes per patient; range one to four needle passes). The difference in the number of needle passes was not statistically significant between groups. The final diagnosis was definite in 53% in group I compared with 77% in group II (P=0.01). The percentage of inconclusive diagnoses was 47% in group I and 23% in group II (P=0.001).

CONCLUSION: Onsite cytotechnologist interpretation of adequacy of tissue sampling significantly improves the diagnostic yield of EUS-FNA. This appears to be independent of the total number of needle passes undertaken for tissue sampling.

Key Words: Biopsy, Endosonography, Outcome

Endoscopic ultrasound (EUS) is a well-established modality in diagnosing and staging various gastrointestinal, pancreaticobiliary and pulmonary cancers (1-4). However, with an accuracy of 82%, EUS alone is limited in its ability to discriminate between malignant and benign lesions (5-7). In the early 1990s, EUS-guided fine-needle aspiration (EUS-FNA) emerged as a minimally invasive technique to obtain cytological specimens from lesions within, or immediately adjacent to, the upper or lower gastrointestinal tract. In experienced hands, EUS-FNA has a proven accuracy with a diagnostic yield for the detection of various malignancies of approximately 90% (8-13).

A successful cytological diagnosis following EUS-FNA requires an experienced endosonographer, a specimen of adequate cellularity, a high-quality cytology slide preparation and an astute cytopathologist. Up to 32% of FNA interpretation may be nondiagnostic due to scant cellularity and/or poor slide preparation causing ‘crush artefact’ when performed by inexperienced personnel (14). Onsite interpretation of FNA specimens is beneficial for rapid clinical diagnosis and decision-making (14-17). Because of a shortage of trained cytopathologists, most centres do not have provisions for onsite diagnosis of EUS-FNA specimens (5,14,18,19). Under these circumstances, it is recommended to perform between five and seven needle passes for pancreatic mass aspiration and between three and five needle passes for liver mass and lymph node aspiration to enhance diagnostic accuracy (20,21). The cytology slides are usually prepared by an endoscopy nurse and later sent to the pathology department for subsequent review by a cytopathologist.

©2009 Pulsus Group Inc. All rights reserved

Can J Gastroenterol Vol 23 No 1 January 2009
A skilled cytotechnologist, if available in the endoscopy suite during EUS-FNA, can enhance the quality of direct smears to limit the amount of crush and air drying artefact and perform onsite staining to assess for adequacy of tissue sampling, thereby increasing the accuracy for obtaining a definitive diagnosis and reducing the need for additional needle passes.

The aim of the present study was to determine whether onsite cytotechnologist interpretation improves the diagnostic yield of solid mass EUS-FNA.

PATIENTS AND METHODS

Between September 2005 and August 2007, all patients undergoing EUS-FNA for solid mass lesions at the University of Alberta Hospital, Edmonton, Alberta, were reviewed and divided into two groups.

EUS-FNA examination

During the study period, all procedures were performed by a single experienced endosonographer using the Pentax EG3630U or EG3630UT curvilinear array echoendoscope (Pentax Precision Instruments, USA). EUS-FNA was performed using a 22-gauge Wilson-Cook Echotip or Echotip-ultra needle (Wilson-Cook, USA). All patients provided informed consent before undergoing the procedure. Procedures were performed in the endoscopy suite under conscious sedation with midazolam and meperidine. A second procedure was completed in selected patients if the initial EUS-FNA was considered inconclusive for diagnosis.

Group I: Without onsite cytotechnologist

Group I included patients who had undergone EUS-FNA between September 1, 2005, and August 31, 2006. The number of needle passes for FNA was at the discretion of the endosonographer and was determined by the degree of difficulty or when it appeared that adequate material had been obtained. The aspirated specimen was smeared onto cytology slides by the assisting endoscopy nurse. One-half of the prepared slides were fixed with an alcohol-based fixative and the other half were air-dried. All slides were then sent to the pathology department for final cytopathological interpretation.

Group II: Onsite cytotechnologist

Group II included patients who had undergone EUS-FNA between September 1, 2006, and August 31, 2007. At the start of the procedure, the cytotechnologist was notified so that he/she could be in the endoscopy suite by the time the first needle pass was completed. The cytotechnologist prepared all slides to limit the amount of crush and air drying artefact and perform onsite staining to assess for adequacy of tissue sampling. If the target lesion was considered to have been satisfactorily sampled, additional needle passes were undertaken only at the discretion of the endosonographer. These additional specimens, when obtained, were stored in a liquid medium for subsequent cell block preparation. All specimens obtained and/or stained in the endoscopy suite were then taken by the cytotechnologist to the pathology department for final cytopathological interpretation.

Outcome measures

Based on the pathologist’s report, the final cytopathological diagnosis was categorized into two major categories: definite (definitely positive or definitely negative); and inconclusive. The primary outcome was the difference in the number of definite and inconclusive diagnostic categories between group I and group II. A secondary outcome was the difference in the number of needle passes undertaken in the two groups.

Ethics

The study was approved by the institutional Health Research Ethics Board of the University of Alberta including review of patient charts.

Statistical analysis

The statistical analysis was performed using the Internet-based Simple Interactive Statistical Analysis software. The t-test was used to analyze the difference between groups I and II (95% CIs) and confirmed the P values with the χ² and Pearson statistic. Statistical significance was set at P=0.05.

RESULTS

The patient demographics and procedure characteristics for group I and group II are shown in Table 1. In both groups, sex distribution was almost equal (51% women). The patients in group I were slightly older than group II with a mean age of 65 years (range 23 to 84 years) versus the mean age of 61 years (range 26 to 86 years) for group II, respectively. The distribution of EUS-FNA target sites was comparable between the two groups (Table 1). Solid masses in the pancreas were the most common FNA target site in both groups (45% in group I versus 37% in group II). This was followed by mediastinal lymph nodes and abdominal lymph nodes or masses (25% and 18% in group I versus 25% and 23% in group II, respectively). A total of 49 EUS-FNA procedures were performed in 47 patients in group I whereas 60 EUS-FNA procedures were performed in 55 patients in group II. The total number of needle passes in group I was 105 (mean 2.14 per patient; range one to five needle passes) versus 158 in group II (mean 2.63 per patient; range one to four needle passes). This difference was not statistically significant.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Group I</th>
<th>Group II</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite</td>
<td>26 (53)</td>
<td>46 (77)</td>
<td>0.01</td>
</tr>
<tr>
<td>Inconclusive</td>
<td>23 (47)</td>
<td>14 (23)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

EUS-FNA Endoscopic ultrasound-guided fine-needle aspiration; NS Not significant

TABLE 1

Patient demographics and procedure characteristics

<table>
<thead>
<tr>
<th></th>
<th>Group I</th>
<th>Group II</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>47</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>EUS-FNA procedures, n</td>
<td>49</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Age, years, mean (range)</td>
<td>65 (23–84)</td>
<td>61 (26–86)</td>
<td></td>
</tr>
<tr>
<td>Men:women</td>
<td>23:24</td>
<td>27:28</td>
<td></td>
</tr>
<tr>
<td>Fine-needle aspiration target site, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic mass</td>
<td>22 (45)</td>
<td>22 (37)</td>
<td></td>
</tr>
<tr>
<td>Mediastinal mass</td>
<td>12 (25)</td>
<td>15 (27)</td>
<td></td>
</tr>
<tr>
<td>Abdominal mass</td>
<td>9 (18)</td>
<td>14 (22)</td>
<td></td>
</tr>
<tr>
<td>Submucosal mass</td>
<td>4 (8)</td>
<td>4 (7)</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>2 (4)</td>
<td>5 (8)</td>
<td></td>
</tr>
<tr>
<td>Needle passes, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>105</td>
<td>158</td>
<td>NS</td>
</tr>
<tr>
<td>Per patient, mean (range)</td>
<td>2.14 (1–5)</td>
<td>2.63 (1–4)</td>
<td>NS</td>
</tr>
<tr>
<td>Diagnosis, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definite</td>
<td>26 (53)</td>
<td>46 (77)</td>
<td>0.01</td>
</tr>
<tr>
<td>Inconclusive</td>
<td>23 (47)</td>
<td>14 (23)</td>
<td>0.001</td>
</tr>
</tbody>
</table>
Table 2: Diagnoses and rates of definitely positive and definitely negative endoscopic ultrasound-guided fine-needle aspiration cytology

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Group I: Definitely positive (88%)</th>
<th>Group II: Definitely positive (60%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatic cancer</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Pancreatic neuroendocrine tumour</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Esophageal cancer</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Non-small-cell lung cancer</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Small-cell lung cancer</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Metastatic adenocarcinoma</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal stromal tumour</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>–</td>
<td>2</td>
</tr>
<tr>
<td>Subtotal</td>
<td>23</td>
<td>37</td>
</tr>
</tbody>
</table>

\*All confirmed on surgical histology

The final cytopathological diagnosis was reported as definite (definitely positive or definitely negative) in 26 of 49 (53%) EUS-FNA procedures in group I compared with 46 of 60 (77%) EUS-FNA procedures in group II (P = 0.01; 95% CI 0.04 to 0.30). Table 2 displays a breakdown of the specific EUS-FNA diagnoses. In the present cohort, three of 26 (12%) patients in group I and nine of 46 (20%) patients in group II were diagnosed as definitely negative, respectively (Table 2). All patients with a definitely negative diagnosis in each group were confirmed benign on surgical histology.

Inconclusive diagnoses were reported in 23 of 49 (47%) EUS-FNA procedures in group I and 14 of 60 (23%) EUS-FNA procedures in group II (P = 0.001; 95% CI –0.48 to 0.13). Of the 23 EUS-FNA procedures with an inconclusive diagnosis in group I, there were four cases (17%) that were reported to have crush artefact (Figure 1) whereas none of the 14 cases with an inconclusive diagnosis in group II were reported to have crush artefact.

**DISCUSSION**

EUS-FNA is an accurate, safe and cost-effective technique to obtain tissue samples for the diagnosis and staging of various luminal and nonluminal gastrointestinal cancers, as well as staging of lung cancer. Published data suggest that the presence of a cytopathologist in the endoscopy suite during EUS-FNA is useful and cost-effective. In a series of 67 patients with metastatic lung cancer (22), EUS-FNA with onsite cytopathology interpretation reported a diagnostic accuracy of 92%, thereby avoiding the need for surgery in 68% of patients. Klapman et al (23) also demonstrated that the presence of an onsite cytopathologist improved the diagnostic yield of EUS-FNA. In this study, EUS-FNA results from two university hospitals were reviewed. At centre 1, 108 patients underwent EUS-FNA in the presence of an onsite cytopathologist. At centre 2, where an onsite cytopathologist was not available, 87 patients underwent EUS-FNA. All procedures at both hospitals were performed by the same endosonographer. At centre 1, a definite diagnosis of positive or negative for malignancy was reported in 78% compared with 52% for centre 2 (P = 0.001), and the proportion of patients with an unsatisfactory specimen was 9% compared with 20% in centre 2 (P = 0.035). Erickson et al (21) also found that the diagnostic yield of EUS-FNA dropped by 10% to 15% when a cytopathologist was not available onsite, in addition to prolonging procedure time and potentially increasing the procedural risk from multiple needle passes.

These data are not limited to EUS-FNA alone. A review of 5688 patients by Nasuti et al (14) proved the diagnostic accuracy and cost-effectiveness of onsite cytopathology evaluation. In this study, all FNA procedures performed by ultrasound, computed tomography, bronchoscopy, fluoroscopy and EUS over a five-year period were included. The proportion of nondiagnostic or inconclusive specimens, defined as inadequate cellularity, was 0.98%. This rate was compared with the published rate of nondiagnostic FNA (20%) when onsite cytopathology evaluation was not used. The authors also report a cost benefit of US$404,000 per year by reducing the number of repeat FNA procedures for nondiagnostic specimens. Cost savings by preventing repeat procedures have also been shown by other investigators (24, 25).

Chang et al (9) reported that in the presence of an onsite cytopathologist during EUS-FNA, adequate specimens were obtained in 100% of patients compared with only 29% in the absence of an onsite cytopathologist. This discrepancy ultimately caused a change in policy at their centre requiring that all EUS-FNA procedures be performed in the presence of an onsite cytopathologist. However, resource and staff limitations do not support the widespread implementation of such a policy.

Cytotechnologists, on the other hand, are less resource-intensive but trained to optimally process cytological specimens and assess for adequacy of target tissue sampling. This minimizes the incidence of crush and air-drying artefacts seen with slides prepared by less-experienced individuals, and ensures adequacy of sample cellularity. In our study, we have demonstrated that onsite processing and interpretation of cytological specimens by a cytotechnologist had a significant impact on the diagnostic yield of EUS-FNA. To our knowledge, the impact of an onsite cytotechnologist has not been reported previously.

There are, however, some limitations in the design of our study. The present study was a single-centre retrospective review of a relatively small number of patients. Although the same endosonographer performed all procedures, not all samples were handled and prepared by the same endoscopy nurse or cytotechnologist and they were not all interpreted by the same cytopathologist. This may have led to differences in preparation and interpretation, but these limitations cannot be avoided in tertiary hospitals that have multiple personnel providing a specific service. A factor that has not been well described in the literature is the ability of individual cytotechnologists to differentiate the glandular cells obtained from the target lesion from those contaminating the needle during its passage across the...
glandular epithelium of the gastrointestinal wall. Perhaps this
could explain some of the false-positive interpretations of
adequate specimen cellularity in group II and could possibly be
an explanation for the relatively low diagnostic yield of 77% in
this group. This, however, is purely speculative and must be stud-
ied in further detail, especially if provisions for onsite cytotech-
tology interpretation are to increase in the future.

Another drawback of our study is the number of needle passes
undertaken for EUS-FNA. Although there was no significant
difference in the mean number of needle passes between the two
groups, group I (without an onsite cytotechnologist) only had a
mean of 2.14 needle passes per patient. Depending on the tar-
geted site, it is recommended to perform five to seven needle
passes on pancreatic lesions and two to five needle passes on
lymph nodes when a cytopathologist is not available in the
endoscopy suite (20,21). Therefore, we recognize this as a poten-
tial shortcoming of our study and realize that the diagnostic
accuracy could have been increased in group I by increasing
the number of needle passes undertaken. However, even if we
speculate that the diagnostic yield of EUS-FNA can be improved
significantly by increasing the number of needle passes, we have
shown that with the presence of an onsite cytotechnologist, we
can achieve high diagnostic yields by reducing the average
number of needle passes although EUS-FNA, generally speak-
ing, is a fairly safe intervention. Limiting the number of needle
passes, in our experience, are in situations of technical difficulty
such as those encountered with tumours of the uncinate process
of the pancreas or when tissue vascularity precludes multiple
needle passes.

**Conclusion**

Our study shows that onsite cytotechnologist interpretation
during EUS-FNA has a significant clinical impact by increasing
the diagnostic yield of EUS-FNA. Although a cost analysis
was not performed as part of the present study, one can specu-
late this approach to be cost-saving by preventing repeat pro-
cedures. We therefore recommend allocating a cytotechnologist
for onsite interpretation for adequacy of tissue sampling in cen-
tres where the services of a cytopathologist are not available.
ACKNOWLEDGEMENTS: The authors acknowledge Stephen Wreakes, Medical Photography, Capital Health, for his assistance with the photographic images and Raj Sandha for her assistance with the statistical analysis.

NOTE: The present study was presented as a poster at the Annual Meeting of the Canadian Association of Gastroenterology/Canadian Digestive Diseases Week, February 29-March 4, 2008, Montreal, Quebec.

REFERENCES